DETECCION MOLECULAR DE REORDENAMIENTOS ASOCIADOS A DESORDENES ONCOHEMATOLOGICOS.

METODO:   RT- PCR NESTED MULTIPLEX DE ALTA SENSIBILIDAD

CODIGO INTERNO: BM 308    

 

TIPO DE MUESTRA

ESTABILIDAD

INFORME (1)

Tº AMB.

4-8ºC

-20ºC

48 A 72 HS

 

MEDULA OSEA CON EDTA

24 HS

24 – 48 HS

CUALITATIVO CON

DETALLE DE LA TRANSLOCACION HALLADA Y ASOCIACION DOCUMENTADA

SANGRE PERIFERICA CON EDTA

24 HS

24 – 48 HS

CUALITATIVO CON

DETALLE DE LA TRANSLOCACION HALLADA Y ASOCIACION DOCUMENTADA

BIOPSIA EN  SOL. FISIOLOGICA ESTERIL

24 HS

24 – 48 HS

CUALITATIVO CON

DETALLE DE LA TRANSLOCACION HALLADA Y ASOCIACION DOCUMENTADA

(1) La nomenclatura utilizada para la identificación de los genes involucrados en el presente estudio, ha sido actualizada de acuerdo al HUGO Human Gene Nomenclature Committee

DESCRIPCION DE LA METODOLOGIA IMPLEMENTADA:

RT- PCR NESTED MULTIPLEX DE ALTA SENSIBILIDAD:

 

Screening para la detección cualitativa de veintinueve transcriptos de reordenamientos moleculares, que comprometen ochenta y tres puntos de ruptura y variantes alternativos, descriptos como marcadores específicos  de entidades oncohematológicas agudas y crónicas, según consta en la bibliografía consultada. Los productos de amplificación obtenidos en este ensayo son posteriormente sometidos a tinción con Bromuro de Etidio y electroforesis en gel de agarosa, definiendo la presencia o ausencia de productos de fusión  correspondientes a las alteraciones cromosómicas que a continuación se detallan:

 

ALTERACION CROMOSOMICA

GENES INVOLUCRADOS

PRODUCTOS DE FUSION

TAMAÑO DEL FRAGMENTO DE PCR

BIBLIOGRAFIA

t(X;11)(q13;q23)

MLL(11q23) FOXO4(Xq13.1)

MLL ex 8/FOXO4: 491 bp

1

t(6;11)(q27;q23)

MLL(11q23) MLLT4(6q27)

MLL ex 6/MLLT4: 308 bp

MLL ex 7/MLLT4: 441 bp

2 ; 3

t(11;19)(q23;p13.1)

MLL(11q23) ELL(19p13.1)

MLL ex 7/ELL: 464 bp

MLL ex 7/ELL-ins120: 584 bp

MLL ex 8/ELL-ins120: 697 bp

4; 5; 6

t(1;11)(p32;q23)

MLL(11q23)

EPS15 (1p32)

MLL ex 6/EPS15: 183 bp

7

t(11;17)(q23;q12-21)

MLL(11q23) MLLT6(17q21)

MLL ex 5/MLLT6: 303bp

8

t(11;19)(q23;p13.3)

MLL(11q23) MLLT1(19p13.3)

MLL ex 6/MLLT1(A): 186 bp

MLL ex 7/MLLT1(A): 318 bp

MLL ex 8/MLLT1(A): 432 bp

30; 32; 34

t(10;11)(p12;q23)

MLL(11q23) MLLT10(10p12)

MLL ex 6/MLLT10 (979): 268bp

MLL ex 7/MLLT10 (979): 400bp

MLL ex 6/MLLT10 (883): 364bp

MLL ex 7/MLLT10 (883): 496bp

MLL ex 6/MLLT10 (787): 460bp

9; 10; 12

t(9;11)(p22;q23)

MLL(11q23) MLLT3(9p22)

MLL ex 6/MLLT3(B): 367 bp

3; 30; 35

t(1;19)(q23;p13)

TCF3(19p13.3) PBX1(PRL)(1q23.3)

TCF3/PBX : 376 bp

TCF3/PBX (ins 27 bp): 403 bp

13; 14; 15

t(17;19)(q22;p13)

TCF3(19p13.3) HLF(17q22)

TCF3ex12/HLFex4: 207 bp

TCF3ex13/HLFex4(ins59): 389 bp

TCF3ex13/HLFex4(ins87): 417 bp

16; 17; 18

t(12;21)(p13;q22)

ETV6(12p13) RUNX1(21q22.3)

ETV6/RUNX1ex2: 428 bp

ETV6/RUNX1ex2?ex3: 174 bp (Splice variant)

ETV6/RUNX1ex3: 389 bp

ETV6/RUNX1ex3?ex3: 135 bp (Splice variant)

19; 20; 21; 55

TAL1d (40 kb deletion)

STIL(1p32)

TAL1(1p32)

STIL/TAL1 d1+d2: 184 bp

22; 23

t(8;21)(q22;q22)

RUNX1(21q22.3) RUNX1T1(8q22)

RUNX1 ex5/RUNX1T1: 197 bp

24; 25; 26

t(3;21)(q26;q22)

RUNX1(21q22.3) MDS1(3q26)

RUNX1ex5/MDS1: 291 bp

RUNX1ex6/MDS1: 483 bp

25; 27; 28

t(16;21)(p11;q22)

FUS(16p11.2)

ERG(21q22.3)

a: FUS(ins44bp,ex7)/ERG(ex9): 313 bp

b: FUS(ex7)/ERG(ex9): 269 bp

c: FUS(ex6)/ERG(ex9): 234 bp

d: FUS(ex8)/ERG(ex7): 407 bp

29; 57

t(15;17)(q22;q12)1

PML(15q22)

RARA(17q12)

PML ex3/ RARA ex3: 325 bp

PML ex3?/ RARA ex3: <325 bp (splice variants)

50; 51; 52

t(4;11)(q21;q23)

MLL(11q23)

AFF1(4q21.3)

MLL ex 6/AFF1 (1414): 319 bp

MLL ex 7/AFF1 (1414): 451 bp

MLL ex 8/AFF1 (1414): 565 bp

MLL ex 6/AFF1(1459): 277 bp

MLL ex 7/AFF1(1459): 409 bp

MLL ex 8/AFF1(1459): 523 bp

MLL ex 7/AFF1(1546): 322bp

MLL ex 8/AFF1(1546): 436bp

30; 31; 32; 33

t(10;11)(p12;q23)

MLL(11q23)

MLLT10(10p12)

MLL ex 5/MLLT10 (2222): 202 bp

MLL ex 6/MLLT10 (2110): 388 bp

MLL ex 5/MLLT10 (1931): 493 bp

9; 10; 11

t(11;19)(q23;p13.3)

MLL(11q23)

MLLT1(19p13.3)

MLL ex 6/MLLT1(B): 315 bp

30; 34

t(9;11)(p22;q23)

MLL(11q23)

MLLT3(9p22)

MLL ex 6/MLLT3(A): 322 bp

MLL ex 7/MLLT3(A): 454 bp

MLL ex 8/MLLT3(A): 568 bp

3; 30; 35

inv(16)(p13;q22)

CBFB (16q22.1)

MYH11 (16p13.11)

CBFB/MYH11(D): 288 bp

CBFB/MYH11(E): 495 bp

CBFB/MYH11(G): 192 bp

CBFB/MYH11(H): 299 bp

47

t(9;22)(q34;q11)

BCR(22q11)

ABL1(9q34.1)

BCR/ABL1b2a2: 397 bp

BCR/ABL1b3a2: 472 bp

BCR/ABL1c3a2: 1012 bp

BCR/ABL1b2a3: 223 bp

BCR/ABL1b3a3: 298 bp

37; 38; 39

t(9;12)(q34;p13)

ETV6(12p13)

ABL1(9q34.1)

ETV6/ABL1 (A): 595 bp

ETV6/ABL1(B): 1141 bp

40; 41

t(5;12)(q33;p13)

ETV6(12p13)

PDGFRB(5q33)

ETV6/PDGFRB: 464 bp

42

t(12;22)(p13;q11-12)

ETV6(12p13)

MN1(22q12.1)

ETV6/MN1(I): 243 bp

ETV6/MN1(2): 408 bp

43

t(6;9)(p23;q34)

DEK(6p23)

NUP214(9q34)

DEK/NUP214: 320 bp

44

t(11;17)(q23;q12-21)

ZBTB16(11q23)

RARA(17q12)

ZBTB16(A)/RARA ex3: 285 bp

ZBTB16(B)/RARA ex3: 372 bp

48; 49

t(3;21)(q26;q22)

RUNX1(21q22.3)

EVI1(3q26)

RUNX1ex5/EVI1ex2: 326 bp

RUNX1ex5/EVI1ex3: 190 bp

RUNX1ex5/EVI1ex2: 664 bp

RUNX1ex6/EVI1ex2: 856 bp

25; 27; 28

t(15;17)(q22;q12)2

PML(15q22)

RARA(17q12)

PML ex6/ RARA ex3: 353 bp

PML ex6D(+/-)ins/ RARA ex3: +/-353bp

50; 51; 52

t(5;17)(q35;q12)3

NPM1(5q35)

RARA(17q12)

NPM1(S)/RARA: 91 bp

NPM1(L)/RARA: 220 bp

53

t(3;5)(q25.1;q35)4

NPM1(5q35)

MLF1(3q25.1)

NPM1/MLF1: 276 bp

54

t(9;22)(q34;q11)

BCR(22q11)

ABL1(9q34.1)

BCR/ABL1e1a2: 320 bp

BCR/ABL1e6a2 962 bp

BCR/ABL1e1a3: 146 bp

37; 38;

 

Bibliografía:

 

1. Parry P., Wei Y., Evans G.: Cloning and characterization of the t(X;11) breakpoint from a leukemic cell lineidentify a new member of the forkhead family. Genes Chromosomes Cancer. 11: 79, 1994.

2. Prasad R., Gu Y., Alderr, H., Nakamura, T., Canaani O., Saito H., Huebner K., Gale R.P.,Nowell P.C.,Kuryiama K et al. Cloning of the All-1 fusion partner, The AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res. 53: 5624, 1993.

3. Poirel H., Rack K., Delabesse E., Radford Weiss I., Troussard X., Debert C., Leboeuf D., bastard C., Pichard F., Veil Buzyn A., Flandrin G., Bernard O., and Macintyre E.: Incidence and characterization of MLL gene(11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 87: 2496, 1996.

4. 4: Thirman MJ., Levitan DA., Kobayashi H., Simon MC., and Rowley JD.: Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc. Natl. Acad. Sci., USA 91: 12110, 1994.

5. Mitani K., Kanda Y., Ogawa S., Tanaka T., Inazawa J., Yazaki Y., and Hirai H.: Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation. Blood 85: 2017,1995.

6. Rubnitz JE., Behm FG., Curcio Brint AM., Pinheiro RP., Carroll AJ., Raimondi SC., Shurtleff SA., and Downing JR.: Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood 87: 4804, 1996.

7. Bernard OA., Mauchauffe M., Mecucci C., Van den Berghe H., and Berger R.: A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL. Oncogene 9: 1039, 1994.

8. Prsasd R., Leshkowitz D., Gu Y., Alder H., Nakamura T., Saito H., Huebner K., Berger R., Croce CM., and Canaani E.: Leucine-zipper dimerization motif encoded by the AF17 gene fused to ALL-1 (MLL) in acute leukemia. . Proc. Natl. Acad. Sci., USA 91: 8107, 1994.

9. Chaplin T., Ayton P., Bernard OA., Saha V., Della Valle V., Hillion J., Gregorini A., Lillington D., Berger R., and Young BD.: A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood 85: 1435, 1995.

10. Chaplin T., Bernard O., Beverloo HB., Saha V., Hagemeijer A., Berger R., and Young BD.: The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 86: 2073, 1995.

11. Hjorth-Sørensen B., Pallisgaard N., Grønholm M., Hokland P., Clausen N., and Jørgensen P.: A novel MLLAF10 fusion mRNA variant in a patient with acute myeloid leukemia detected by a new asymmetric reverse transcription PCR method. Leukemia 11: 1588, 1997.

12. Borkhardt A., Haas OA., Strobl W., Repp R., Mann G., Gadner H., and Lampert F.: A novel type of MLL/AF10 fusion transcript in a child with acute megakaryocytic leukemia (AML-M7). Leukemia 9: 1796, 1995.

13. Kamps MP., Murre C., Sun XH., and Baltimore D.: A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 60: 547, 1990.

14. Nourse J., Mellentin JD., Galili N., Wilkinson J., Stanbridge E., Smith SD., and Cleary ML.: Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 60: 535, 1990.

15. Izraeli S., Kovar H., Gadner H., and Lion T.: Unexpected heterogeneity in E2A/PBX1 fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia. Blood 80:1413, 1992.

16. 16: Hunger SP., Ohyashiki K., Toyama K., and Cleary ML.: Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 6:1608, 1992.

17. Inaba T., Roberts WM., Shapiro LH., Jolly KW., Raimondi SC., Smith SD., and Look AT.: Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 257: 531, 1992.

18. Hunger SP., Devaraj PE., Foroni L., Secker Walker LM., and Cleary ML.: Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. Blood 83: 2970, 1994.

19. Romana SP., Poirel H., Le Coniat M., Flexor MA., Mauchauffe M., Jonveaux P., Macintyre EA., Berger R.,and Bernard OA.: High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86:4263, 1995.HemaVision Revision 25 date 2009-05-26

20. Romana SP., Mauchauffe M., Le Coniat M.,ChumakovI., Le Paslier D., Berger R., and Bernard OA.: Thet(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85: 3662, 1995.

21. Golub TR., Barker GF., Bohlander SK., Hiebert SW., Ward DC., Bray Ward P., Morgan E.,RaimondiSC.,Rowley JD., and Gilliland DG.: Fusion of the TEL gene on 12P13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci.,USA92: 4917, 1995.

22. Bash RO., Crist WM., Shuster JJ., Link MP., Amylon M., Pullen J., Carroll AJ., Buchanan GR., Smith RG.,and Baer R.: Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group stude. Blood 81: 2110, 1993.

23. Aplan PD., Lombardi DP., Ginsberg AM., Cossman J., Bertness VL., and Kirsch IR.: Disruption of the human SCL locus by ”illegitimate” V-(D)-J recombinase activity. Science 250: 1426, 1990.

24. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., Kamada N., and Ohki M.: The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J.12: 2715, 1993.

25. Nucifora G., and Rowley JD.: AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86: 1, 1995.

26. Downing JR., Head DR., Curcio Brint AM., Hulshof MG., Motroni TA., Raimondi SC., Carroll AJ., Drabkin HA., Willman C., and Theil KS.: An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 81: 2860, 1993.

27. Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa M., Mano H., Yazaki Y., Ohki M., and Hirai H.: Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13: 504, 1994.

28. Nucifora G., Begy CR., Kobayashi H., Roulston D., Claxton D., Pedersen-Bjergaard J., Parganas E., Ihle JN., and Rowley JD.: Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc. Natl. Acad. Sci., USA 91: 4004, 1994.

29. Ichikawa H., Shimizu K., Hayashi Y., and Ohki M.: An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54: 2865, 1994.

30. Yamamoto K., Seto M., Iida S., Komatsu H., Kamada N., Kojima S., Kodera Y., Nakazawa S., Saito H., and Takahashi T.: A reverse transcriptase-polymerase chain reaction detects heterogenous chimeric mRNAs in leukemias with 11q23 abnormalities. Blood 83: 2912, 1994.

31. Biondi A., Rambaldi A., Rossi V., Elia L., Caslini C., Basso G., Battista R., Barnui T., Mandelli F., and Masera G.: Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 82: 2943, 1993.

32. Corral J., Forster A., Thompson S., Lampert F., Kaneko Y., Slater R., Kroes WG., van der Schoot CE., Ludwig WD., and Karpas A.: Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation. Proc. Natl. Acad. Sci., USA 90: 8538, 1993.

33. Downing JR., Head DR., Raimondi SC., Carrol AJ., Curcio Brint AM., Motroni TA., Hulshof MG., Pullen DJ., and Domer PH.: The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)- containing acute lymphoblastic leukemia. Blood 83: 330, 1994.

34. Yamamoto K., Seto M., Komatsu H., Iida S., Akao Y., Kojima S., Kodera Y., Nakazawa S., Ariyoshi Y., Takahashi T., and Ueda R.: Two distinct portions of LTG19/ENL at 19p13 are involved in t(11;19) leukemia. Oncogene 8: 2617, 1993.

35. Nakamura T., Alder H., Gu Y., Prasad R., Canaani O., Kamada N., Gale R.P., Lange B., Crist W.M., and Nowell P.C.: Genes on chromosome 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc. Natl. Acad. Sci., USA 90: 4631, 1993.

36. Tse W., Zhu W., Chen H.S., and Cohen A.: A novel gene, AF1q, fused to MLL in t(1;11)(q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 85: 650, 1995.

37. Hermans A., Heisterkamp N., von Linden M., van Baal S., Meijer D., van der Plas D., Wiedermann L.M., Groffen J., Bootsma D., and Grosveld G.: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51: 33, 1987.

38. Cross N.C., Melo J.V., Feng L., and Goldman J.M.: An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8: 186, 1994. HemaVision Revision 26 date 2009-05-26

39. Hochhaus, A., Reiter A., Skladny H., Melo J.V., Sick C., Berger U., Guo J.Q., Arlinghaus R.B., Hehlmann R.,Goldman J.M., and Cross N.C.P.: A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88: 2236, 1996.

40. Papadopoulos P., RidgeS.A., BoucherC.A., Stocking C., and Wiedemann L.M.: The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 55: 34, 1995.

41. Andreasson P., Johansson B., Carlsson M., Jarlsfelt I., Fioretos T., Mitelman F., and Höglund M.: BCR/ABLnegative chronic myeloid leukemia with ETV6/ABL fusion. Genes, Chromosomes & Cancer 20: 299, 1997.

42. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G.: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307, 1994.

43. Buijs A., Sherr S., van Baal S., van Bezouw S., van der Plas D., Geurts van Kessel A., Riegman P., Lekanne Deprez R., Zwarthoff E., Hagemeijer A., and Grosveld G.: Translocation (12;22)(p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 10: 1511, 1995.

44. von Lindern M., Fornerod M., van Baal S., Jaegle M., de Wit T., Buijs A., and Grosveld G.: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dec and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol. Cell. Biol. 12: 1687, 1992.

45. von Lindern M., van Baal S., Wiegant j., Raap A., Hagemeijer A., and Grosveld G.: Can, a putative oncogene associated with myeloid leukomogenesis, may be activated by fusion of its 3’half to different genes: characterization of the set gene. Mol. Cell. Biol. 12: 3346, 1992.

46. Nagata K., Kawase H., Handa H., Yano K., Yamasaki M., Ishimi Y., Okuda A., Kikuchi A., and Matsumoto K.: Replication factor encoded by a putative oncogene, set, associated with myeloid leukomogenesis. Proc. Natl. Acad. Sci.,USA92: 4279, 1995.

47. Liu P.P., Hajra A., Wijmenga C., and Collins F.S.: Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 85: 2289, 1995.

48. Chen Z.,BrandN.J., Chen A., Chen S.J., Tong J.H., Wang Z.Y., Waxman S., and Zelent A.: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a varient t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J. 12: 1161, 1993.

49. Licht J.D., Chomienne C., Goy A., Chen A., Scott A.A., Head D.R., Michaux J.L., Wu Y., DeBlasio A., Miller W.H.Jr.: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukaemia associated with translocation (11;17). Blood 85: 1083, 1995.

50. Pandolfi P.P., Alcalay M., Fagioli M., Zangrilli D., Mencarelli A., Diverio D., Biondi A., Lo Coco F., Rambaldi A., and Grignani F.: Genimic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J. 11: 1397, 1992.

51. 51: Yoshida H., Naoe T., Fukutani H., Kiyoi H., Kubo K., and Ohno R.: Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: Sequence non-specific recombination between the PML and RARA genes within identical short stretches. Genes, Chromosomes & Cancer 12: 37, 1995.

52. Kane J.R., Head D.R., Balazs L., Hulshof M.G., Motroni T.A., Raimondi S.C. Carroll A.J., Behm F.G., Krance R.A., Shurtleff S.A., and Downing J.R.: Molecular analysis of the PML/RARalpha chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 10: 1296, 1996.

53. Redner R.L., Rush E.A., Faas S., Rudert W.A. and Corey S.J.: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87: 882, 1996.

54. Yoneda Kato N., Look A.T., Kirstein M.N., Valentine M.B., Raimondi S.C., Cohen K.J., Carroll A.J., and Morris S.W.: The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 12: 265, 1996.

55: Satake N., Kobayashi H., Tsunematsu Y.,KawasakiH., Horikoshi Y., Koizumi S. and Kaneko Y.: Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12,21). British J. of Haematology 97: 607, 1997.

56. Sacchi N., Nisson P.E., Watkins P.C., Faustinella F., Wijsman J. and Hagemeijer A.: AML1 fusion transcripts in t(3,21) positive leukemia: evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts. Genes, Chromosomes & Cancer 11: 226, 1994. HemaVision Revision 27 date 2009-05-26

57. Kong X-T., Ida K.,IchikawaH.,ShimizuK., Ohki M., Maseki N., Kaneko Y., Sako M., Kobayashi Y., Tojou A., Miura I., Kakuda H., Funabiki T., Horibe K., Hamaguchi H., Akiyama Y., Bessho F., Yanagisawa M. and Hayashi Y.: Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16,21)(p11,q22) and identification of a novel transcript. Blood 90: 1192, 1997.

58. Pallisgaard N., Hokland P.,RiishøjD.C., Pedersen B. and Jørgensen P.: Multiplex reverse transcriptionpolymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in Acute Leukemia. Blood 92: 574, 1998.

 

 

RECOMENDACIONES:

UTILIZAR PARA LA OBTENCIÓN, CONSERVACIÓN Y TRANSPORTE DE LAS MUESTRAS, EL KIT PREPARADO POR BIONET A TALES FINES.

 

CONDICIONES DE RECHAZO:

  • MUESTRAS MAL  ROTULADAS
  • MUESTRAS DERRAMADAS
  • MUESTRAS QUE NO CONTEMPLEN LAS NORMAS DE BIOSEGURIDAD EXIGIDAS POR EL LABORATORIO
  • MUESTRAS QUE NO CUMPLAN CON LAS INDICACIONES DE ESTABILIDAD Y CONSERVACION.